جميع الدراسات
التوظيفالمرحلة 3تدخلي

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

This clinical trial is designed for people who have Crohn's disease that is moderately to severely active. Crohn's is a long-term condition affecting the gut. The main goal is to test a new medicine, JNJ-78934804, to understand how well it helps control Crohn's symptoms and if it's safe to use. We’ll be comparing it against another approved medicine called guselkumab over 48 weeks (around 11 months). By doing this, we hope to find new and effective ways to help people living with Crohn's disease manage their condition better.

نظرة سريعة

الحالة
التوظيف
المرحلة
المرحلة 3
الراعي
جانسن للأبحاث والتطوير، ذ.م.م
الهدف من التسجيل
460
ابدأ
٢٢ مايو ٢٠٢٦
التاريخ المتوقع للانتهاء
12 Jul 2030

ما هو موضوع هذه الدراسة؟

Crohn's disease is a type of inflammatory bowel disease (IBD) that causes inflammation in your digestive tract. This can lead to belly pain, severe diarrhoea, tiredness, weight loss, and sometimes serious problems. It’s a long-term condition that can get worse over time, and while there's no cure, medicines can help manage the symptoms and improve quality of life. This study is focusing on people whose Crohn's disease is currently active and causing moderate to severe symptoms.

The main aim of this study is to explore a new treatment called JNJ-78934804. We want to see how effective it is at reducing inflammation and relieving symptoms of Crohn's disease. We'll also be carefully checking for any side effects to make sure it's safe. To do this, we'll compare it with a medicine already approved for similar conditions, called guselkumab. By comparing the two, we can understand if JNJ-78934804 offers a new, effective option for people living with this challenging condition.

Taking part in a study like this is important because it helps scientists and doctors discover new ways to treat diseases. If successful, new medicines can offer hope and better health for many people in the future. The study will last for about 48 weeks, and during this time, your health and Crohn's symptoms will be carefully monitored.

النقاط الرئيسية

  • This study is testing a new medicine (JNJ-78934804) for active Crohn's disease.
  • It aims to see if the new medicine works well and is safe compared to an existing treatment (guselkumab).
  • The study is for adults (18+) with moderately to severely active Crohn's disease.
  • Participation involves regular clinic visits and health checks over about 11 months.
  • You will receive study medicine (likely injections) and be closely monitored.
  • يمكنك الانسحاب من الدراسة في أي وقت دون التأثير على رعايتك العادية.

من قد يكون مؤهلاً؟

To be considered for this study, you need to be an adult (18 years or older) and have been diagnosed with Crohn's disease for at least 12 weeks. Your doctor must have confirmed this diagnosis with a camera test (endoscopy) and tissue samples (biopsy). Your Crohn's disease should currently be moderately to severely active, meaning you have noticeable symptoms like frequent loose stools or belly pain.

Also, a recent camera test of your bowel (colonoscopy or similar) needs to show signs of active Crohn's disease in your small or large intestine. It's important that previous treatments for your Crohn's, such as certain tablets or injections, either haven't worked well enough, stopped working, or caused side effects that meant you couldn't continue with them.

There are also some reasons why you might not be able to join. For example, if you have other types of bowel inflammation like ulcerative colitis, or serious complications of Crohn's disease like blockages that need surgery soon. If you have an ostomy bag, or certain other medical conditions that could make it difficult to properly assess your Crohn's disease, you might also not be suitable. The study team will review all your medical information carefully to see if this study is right for you.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. هل عمرك 18 سنة أو أكثر؟
  2. Do you have a confirmed diagnosis of Crohn's disease (not ulcerative colitis)?
  3. Is your Crohn's disease currently causing moderate to severe symptoms?
  4. Have your previous Crohn's treatments not worked well enough or caused problems?
  5. Do you not have serious Crohn's complications like blockages or an ostomy bag?
  6. Are you able to attend regular clinic appointments for about 11 months?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you decide to take part in this study, you will have regular visits to the clinic over approximately 48 weeks (about 11 months). These visits will involve various health checks, such as physical exams, blood tests, and possibly stool samples. You might also have repeat camera tests of your bowel at certain times to see how your Crohn's is responding to the treatment.

During the study, you will receive one of the study medicines – either JNJ-78934804 or guselkumab. These will likely be given as injections. You'll be given clear instructions on how and when to take your medicine, and the study team will be there to support you and answer any questions you have. Throughout the study, your symptoms and general health will be closely monitored to see how you are responding to the treatment and to identify any side effects. You'll also have follow-up calls or visits after your last dose of study medicine.

المخاطر والفوائد المحتملة

Taking part in any clinical trial involves potential benefits and risks. A potential benefit of joining this study is that you might receive a new treatment that could improve your Crohn's symptoms and overall quality of life. You will also receive careful medical monitoring throughout the study. However, there's no guarantee the new medicine will work for you, and it might not be better than your current treatment. Potential risks could include side effects from the study medicines, which will be carefully explained to you by the study team. You might also need to attend frequent appointments and have various medical tests, which can be time-consuming. It’s very important to remember that you can decide to leave the study at any time, for any reason, without it affecting your usual medical care.

Locations (252)

  • Clinnova Research
    الرمز البريدي المؤكد
    أناهايم، الولايات المتحدة· التوظيف
  • Gastro SB Clinic
    الرمز البريدي المؤكد
    Chula Vista, United States· التوظيف
  • United Medical Doctors
    الرمز البريدي المؤكد
    لوس ألاميتوس، الولايات المتحدة· التوظيف
  • Medical Associates Research Group, Inc.
    الرمز البريدي المؤكد
    سان دييغو، الولايات المتحدة· التوظيف
  • جمعية بيك لأمراض الجهاز الهضمي
    الرمز البريدي المؤكد
    كولورادو سبرينغز، الولايات المتحدة· التوظيف
  • Florida Research Center Inc.
    الرمز البريدي المؤكد
    ليك وود رانتش، الولايات المتحدة· التوظيف
  • Sanchez Clinical Research, Inc
    الرمز البريدي المؤكد
    ميامي، الولايات المتحدة· التوظيف
  • GCP Clinical Research
    الرمز البريدي المؤكد
    تامبا، الولايات المتحدة· التوظيف
  • Atlanta Gastroenterology Specialists
    الرمز البريدي المؤكد
    Suwanee, United States· التوظيف
  • Tri-State Gastroenterology Assoc
    الرمز البريدي المؤكد
    Crestview Hills, United States· التوظيف
  • Gastroenterology Clinic of Acadiana
    الرمز البريدي المؤكد
    Lafayette, United States· التوظيف
  • GIA Metairie
    الرمز البريدي المؤكد
    ميتيري، الولايات المتحدة· التوظيف

أسئلة شائعة

ما هو مرض كرون؟

Crohn's disease is a long-term condition that causes inflammation in your digestive system, leading to symptoms like tummy pain, diarrhoea, and tiredness.

What is JNJ-78934804?

JNJ-78934804 is a new medicine being tested to see if it can help control the inflammation and symptoms of Crohn's disease.

كم ستستغرق مدة الدراسة؟

The main part of the study will last for about 48 weeks, which is roughly 11 months.

هل سأعرف أي دواء أحصل عليه؟

In this type of study, participants usually don't know whether they are receiving the new medicine or the comparison medicine (guselkumab) until after the study is over. This helps ensure fair results.

هل يمكنني مغادرة الدراسة إذا غيرت رأيي؟

Yes, you are free to leave the study at any point, for any reason, and it will not affect your regular medical care.

كيفية معرفة المزيد

جهة الاتصال للدراسة

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "A Study of JNJ-78934804 in Participants With Moderately to S… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.